Abhishek Garg LAB (@abhishekgarglab.bsky.social)

💪#Power of #bispecifics in #cancer #patient #treatment? ✴️Anti-#PD1 x #LAG3 #bispecific had similar anti-#tumour #efficacy vs anti-#PD1/anti-#CTLA4 #combo but with better #safety #profile ⏲️Time to move #multispecifics vs #macrophages where #monos failed! www.nature.com/articles/s41...

loading . . .

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial - Nature Medicine In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, showed the highest pathologic response rate with a better safety profile than the standard treatment approach of ipilimumab plus nivolumab. https://www.nature.com/articles/s41591-025-03967-2